Zepbound® and decreased appetite

Why the US table has no appetite row

Zepbound®’s US label builds Table 1 from two 72-week, placebo-controlled trials: SURMOUNT-1 in adults with obesity or overweight and no diabetes, and SURMOUNT-2 in adults with type 2 diabetes. Entry into the table has two conditions: the reaction must have been reported by at least 2% of people on Zepbound®, and more often than by people on placebo ^[1]. Nausea, diarrhea, vomiting, constipation and a dozen other effects are listed; decreased appetite is not ^[1]. Appetite turns up instead in the pharmacology section, which says tirzepatide lowers calorie intake, probably through appetite, and that both of its target receptors are found in brain areas that regulate eating ^[1].

That framing matches the indication. Zepbound® is approved for two uses in adults, each paired with a reduced-calorie diet and more physical activity: long-term weight reduction for people with obesity, or with overweight plus at least one weight-related condition, and moderate to severe obstructive sleep apnea when obesity is also present ^[1]. Eating less is part of the plan in both.

What trials measured about hunger

Two phase 1 studies in people with obesity, both with Eli Lilly scientists among the authors, looked at eating directly. In a 6-week trial, 114 adults without diabetes and a body mass index of 27 to 50 were randomised to tirzepatide, placebo or open-label liraglutide. By week 3, the tirzepatide group ate far less at a lunch where they could take as much as they liked, and reported lower overall appetite, hunger, cravings and tendency to overeat. Brain scans showed weaker responses to pictures of high-fat, high-sugar foods in several regions ^[5].

A second study paired work in mice with a clinical trial. In the people studied, tirzepatide reduced appetite and intake at a test meal and increased fat burning, but it did not change metabolic adaptation, the slowdown in energy use that usually accompanies weight loss ^[6]. Canada’s monograph sums up the human effect as more fullness and satiety, less hunger, and weaker cravings and preferences for sugary and fatty foods ^[3].

How much less is too little

The SURMOUNT programme offers some reassurance. A post hoc analysis of SURMOUNT-1 to -4, covering 4,726 participants, found investigator-reported events pointing to malnutrition were uncommon: abnormal weight loss in 0.03% and underweight in 0.06% on tirzepatide, against none on placebo. Vitamin deficiency events were similar in the two groups (0.99% and 1.07%), and 0.38% of people on tirzepatide reached a body mass index below 18.5, compared with 0.06% on placebo ^[7]. The authors point out that vitamin and mineral levels were not measured routinely, which limits what the trials can show ^[7].

Everyday eating may look different from a trial. In a small observational study of 28 adults starting semaglutide or tirzepatide without structured nutrition support, total energy intake fell, intake of several micronutrients dropped and diet quality did not improve over 24 weeks; the authors describe the results as exploratory ^[8]. Canada’s monograph names vitamin, mineral and protein deficiency and low body weight as malnutrition risks, and allows for stopping treatment in severe or persistent cases ^[3]. Fatigue, dizziness and weight loss are the general malnutrition symptoms MedlinePlus describes ^[11].

Hunger, blood sugar and other medicines

People with type 2 diabetes who use Zepbound® have one more thing to watch. In SURMOUNT-2, blood sugar below 54 mg/dL was recorded in 4.2% on Zepbound® against 1.3% on placebo, and in 10.3% of those who also took a sulfonylurea ^[1]. Eating very little can make low readings more likely. The Medication Guide asks anyone on insulin or a sulfonylurea to talk about low blood sugar with their provider before starting, and it lists hunger itself among the warning signs, together with shakiness, sweating, a fast heartbeat and confusion ^[2].

Zepbound® also slows stomach emptying, most strongly after the first dose, which can change how other medicines taken by mouth are absorbed ^[1]. If much smaller meals alter the way you take another medicine, ask your pharmacist or prescriber how to handle it.

When poor appetite has another cause

MedlinePlus lists many reasons appetite can fall away besides medicines: sadness, depression or grief, an underactive thyroid, chronic kidney, liver or lung disease, heart failure, the first months of pregnancy, some cancers, and certain drugs, among them codeine, morphine and antibiotics ^[10]. Its advice is to get checked when poor appetite comes together with signs of depression, an eating disorder, or alcohol or drug use ^[10].

Two Zepbound®-specific points follow from that list. Canada asks for monitoring of new or worsening depression and unusual mood changes in people treated for weight management ^[3]. And because the US label says to stop Zepbound® once pregnancy is recognised ^[1], appetite loss with nausea and a late period is a reason to take a pregnancy test.

What may help

MedlinePlus suggests several small meals or nourishing snacks spread through the day when appetite is low, and a diet history, a record of everything you eat and drink over at least a day, to show your provider ^[10]. Canada’s patient information says your prescriber may offer nutrition guidance or recommend vitamins or supplements while you use Zepbound® ^[3]. The Medication Guide stresses drinking fluids to lower the chance of dehydration, and that deserves more attention when meals, and the water they contain, get smaller ^[2].

Bring concrete details to appointments: how many meals you manage, whether nausea, early fullness or plain lack of interest is the barrier, your weight trend and any weakness or dizziness. Whether anything about your treatment changes is your prescriber’s decision.

Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.